Cargando…

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer

PARP inhibitors were recently approved for treatment of molecularly-defined subsets of metastatic castrate-resistant prostate cancer (mCRPC) patients. Although the PARP inhibitor olaparib was approved for use in patients with a mutation in one of fourteen genes, the mutation frequency of the genes v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dillon, Kasia M., Bekele, Raie T., Sztupinszki, Zsofia, Hanlon, Timothy, Rafiei, Shahrzad, Szallasi, Zoltan, Choudhury, Atish D., Mouw, Kent W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242979/ https://www.ncbi.nlm.nih.gov/pubmed/35768576 http://dx.doi.org/10.1038/s41698-022-00291-7

Ejemplares similares

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer
por: Tsujino, Takuya, et al.
Publicado: (2023)

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer
por: Miao, Chenkui, et al.
Publicado: (2022)

PALB2 self-interaction controls homologous recombination
por: Buisson, Rémi, et al.
Publicado: (2012)

Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer
por: Sztupinszki, Zsofia, et al.
Publicado: (2018)

Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer
por: Ozden, Ozkan, et al.
Publicado: (2016)

RNF19A-mediated ubiquitination of BARD1 prevents BRCA1/BARD1-dependent homologous recombination
por: Zhu, Qian, et al.
Publicado: (2021)

Homologous recombination DNA repair defects in PALB2-associated breast cancers
por: Li, Anqi, et al.
Publicado: (2019)

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
por: Póti, Ádám, et al.
Publicado: (2019)

RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage
por: Krais, John J., et al.
Publicado: (2021)

A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures
por: Diossy, Miklos, et al.
Publicado: (2021)

The BARD1/HP1 interaction: Another clue to heterochromatin involvement in homologous recombination
por: Fukuda, Takayo, et al.
Publicado: (2015)

The BRCA1/BARD1 complex recognizes pre-ribosomal RNA to facilitate homologous recombination
por: Wu, Duo, et al.
Publicado: (2023)

Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers
por: Li, Anqi, et al.
Publicado: (2019)

ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer
por: Zhou, Yuzhen, et al.
Publicado: (2023)

Plasticity of BRCA2 Function in Homologous Recombination: Genetic Interactions of the PALB2 and DNA Binding Domains
por: Siaud, Nicolas, et al.
Publicado: (2011)

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
por: Schina, Aimilia, et al.
Publicado: (2023)

A PALB2-interacting domain in RNF168 couples homologous recombination to DNA break-induced chromatin ubiquitylation
por: Luijsterburg, Martijn S, et al.
Publicado: (2017)

PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1
por: Belotserkovskaya, Rimma, et al.
Publicado: (2020)

PARP1 suppresses homologous recombination events in mice in vivo
por: Claybon, Alison, et al.
Publicado: (2010)

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations
por: von Werdt, Alexander, et al.
Publicado: (2021)

Identification of a novel pathogenic variant in PALB2 and BARD1 genes by a multigene sequencing panel in triple negative breast cancer in Morocco
por: Laraqui, Abdelilah, et al.
Publicado: (2021)

H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination in sister chromatids
por: Nakamura, Kyosuke, et al.
Publicado: (2019)

Methylated-UHRF1 and PARP1 interaction is critical for homologous recombination
por: Hahm, Ja Young, et al.
Publicado: (2020)

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
por: Burdova, Kamila, et al.
Publicado: (2019)

Xanthatin synergizes with cisplatin to suppress homologous recombination through JAK2/STAT4/BARD1 axis in human NSCLC cells
por: Zhang, Jian, et al.
Publicado: (2021)

A major genetic accelerator of cancer diagnosis: rs867228 in FPR1
por: Sztupinszki, Zsofia, et al.
Publicado: (2021)

Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity
por: Adamovich, Aleksandra I., et al.
Publicado: (2019)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
por: Janysek, Dawn C., et al.
Publicado: (2021)

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
por: Xu, Junfen, et al.
Publicado: (2021)

PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
por: O’Sullivan Coyne, Geraldine, et al.
Publicado: (2022)

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature
por: Batalini, Felipe, et al.
Publicado: (2023)

BARDES coming of age?
Publicado: (2022)

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma
por: Prosz, Aurel, et al.
Publicado: (2023)

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma
por: Prosz, Aurel, et al.
Publicado: (2023)

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition
por: Principe, Daniel R.
Publicado: (2022)

PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
por: Sugimura, Kazuto, et al.
Publicado: (2008)

PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways
por: Beck, Carole, et al.
Publicado: (2014)

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
por: Lahiguera, Álvaro, et al.
Publicado: (2020)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ik4q566t7rh2vmrd6egknbc6t5